NP-18-2 Oral Capsule - Phase 2a clinical program

5-HT1A Agonist and Sigma-1 agonist/antagonist

Oral Swallowed Capsule - Phase 1 & 2 clinical studies

The figure on the right shows the docked pose of NP-18-2

in the binding pocket of the Sigma-1 receptor (PDB ID: 6DK1)

NP-18-2 is an orally-bioavailable selective full agonist to the 5-Hydroxytryptamine receptor 1A (5-HT1A) and a ligand for the Sigma-1 receptor. NP-18-2 is a highly potent (Ki = 5.1-17 nM) 5-HT1A agonist in radioligand binding assays. NP-18-2 also demonstrates selective binding to the Sigma-1 receptor (Ki = 100 nM) in radioligand binding assays.

An oral capsule formulation of NP-18-2 has completed multiple Phase 1 and 2 clinical studies and is currently in Phase 2 clinical development.

Intellectual Property

A new composition-of-matter patent will be filed in the next year.